SK277922B6 - 2 ranitidine hydrochloride form, method of its preparation and pharmaceutical product with its contents - Google Patents
2 ranitidine hydrochloride form, method of its preparation and pharmaceutical product with its contents Download PDFInfo
- Publication number
- SK277922B6 SK277922B6 SK4035-91A SK403591A SK277922B6 SK 277922 B6 SK277922 B6 SK 277922B6 SK 403591 A SK403591 A SK 403591A SK 277922 B6 SK277922 B6 SK 277922B6
- Authority
- SK
- Slovakia
- Prior art keywords
- ranitidine hydrochloride
- ranitidine
- vwd
- excipient
- 2vwd
- Prior art date
Links
- GGWBHVILAJZWKJ-KJEVSKRMSA-N ranitidine hydrochloride Chemical group [H+].[Cl-].[O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 GGWBHVILAJZWKJ-KJEVSKRMSA-N 0.000 title claims abstract description 80
- 238000000034 method Methods 0.000 title claims description 19
- 238000002360 preparation method Methods 0.000 title claims description 9
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 8
- 229940127557 pharmaceutical product Drugs 0.000 title claims description 8
- 229960001520 ranitidine hydrochloride Drugs 0.000 claims abstract description 44
- 239000002904 solvent Substances 0.000 claims abstract description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 63
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 36
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- 238000002425 crystallisation Methods 0.000 claims description 15
- 230000008025 crystallization Effects 0.000 claims description 15
- 229960000620 ranitidine Drugs 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 8
- 238000001953 recrystallisation Methods 0.000 claims description 7
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 5
- 238000002441 X-ray diffraction Methods 0.000 claims description 5
- 238000002329 infrared spectrum Methods 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 239000002480 mineral oil Substances 0.000 claims description 3
- 241000792859 Enema Species 0.000 claims description 2
- 239000007920 enema Substances 0.000 claims description 2
- 239000007937 lozenge Substances 0.000 claims description 2
- 230000014759 maintenance of location Effects 0.000 claims description 2
- 235000010446 mineral oil Nutrition 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- VMXUWOKSQNHOCA-UKTHLTGXSA-N ranitidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-UKTHLTGXSA-N 0.000 claims 3
- 230000005855 radiation Effects 0.000 claims 2
- 238000005169 Debye-Scherrer Methods 0.000 claims 1
- 239000012296 anti-solvent Substances 0.000 claims 1
- 229940095399 enema Drugs 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 abstract description 3
- 230000000172 allergic effect Effects 0.000 abstract description 2
- 208000010668 atopic eczema Diseases 0.000 abstract description 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000025865 Ulcer Diseases 0.000 abstract 1
- 150000001298 alcohols Chemical class 0.000 abstract 1
- 210000004051 gastric juice Anatomy 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 231100000397 ulcer Toxicity 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 24
- 239000000047 product Substances 0.000 description 20
- 239000000203 mixture Substances 0.000 description 13
- 239000000725 suspension Substances 0.000 description 12
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 6
- 239000013078 crystal Substances 0.000 description 5
- 239000011928 denatured alcohol Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000001914 filtration Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- ZPLCXHWYPWVJDL-UHFFFAOYSA-N 4-[(4-hydroxyphenyl)methyl]-1,3-oxazolidin-2-one Chemical compound C1=CC(O)=CC=C1CC1NC(=O)OC1 ZPLCXHWYPWVJDL-UHFFFAOYSA-N 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000011549 crystallization solution Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- -1 for example Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8031634 | 1980-10-01 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK403591A3 SK403591A3 (en) | 1995-08-09 |
| SK277922B6 true SK277922B6 (en) | 1995-08-09 |
Family
ID=10516407
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK4035-91A SK277922B6 (en) | 1980-10-01 | 1991-12-23 | 2 ranitidine hydrochloride form, method of its preparation and pharmaceutical product with its contents |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US4521431A (https=) |
| JP (1) | JPS5791983A (https=) |
| KR (1) | KR870001431B1 (https=) |
| AT (1) | AT389696B (https=) |
| AU (1) | AU549119B2 (https=) |
| BE (1) | BE890574A (https=) |
| CA (1) | CA1202638A (https=) |
| CH (1) | CH652122A5 (https=) |
| CZ (1) | CZ280885B6 (https=) |
| DE (1) | DE3139134A1 (https=) |
| DK (2) | DK167794B1 (https=) |
| ES (1) | ES8301954A1 (https=) |
| FR (1) | FR2491067A1 (https=) |
| GR (1) | GR72499B (https=) |
| HK (1) | HK97985A (https=) |
| IE (1) | IE51604B1 (https=) |
| IL (1) | IL63968A (https=) |
| IT (1) | IT1143237B (https=) |
| KE (1) | KE3549A (https=) |
| LU (1) | LU83661A1 (https=) |
| MY (1) | MY8500747A (https=) |
| NL (1) | NL8104482A (https=) |
| NZ (1) | NZ198522A (https=) |
| PH (2) | PH19489A (https=) |
| PT (1) | PT73744B (https=) |
| SE (1) | SE453500B (https=) |
| SK (1) | SK277922B6 (https=) |
| ZA (1) | ZA816809B (https=) |
| ZW (1) | ZW24481A1 (https=) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1279328C (en) * | 1983-07-15 | 1991-01-22 | Janos Borvendeg | Process for preparing basic thioethers and the salts thereof |
| GB8629781D0 (en) * | 1986-12-12 | 1987-01-21 | Glaxo Group Ltd | Pharmaceutical compositions |
| SE8704436D0 (sv) * | 1987-11-13 | 1987-11-13 | Pm Konsult Handelsbolag | Anvendning av antisekretoriska substanser for nya indikationer |
| IL90245A (en) * | 1988-05-11 | 1994-04-12 | Glaxo Group Ltd | Resin adsorbate comprising ranitidine together with a synthetic cation exchange resin, its preparation and pharmaceutical compositions containing it |
| GB8904182D0 (en) * | 1989-02-23 | 1989-04-05 | Glaxo Canada | Pharmaceutical compositions |
| US5169864A (en) * | 1991-11-15 | 1992-12-08 | Baxter International Inc. | Unbuffered premixed ranitidine formulation |
| US5338871A (en) * | 1991-12-20 | 1994-08-16 | Torcan Chemical Ltd. | Preparation of form 1 ranitidine hydrochloride |
| CN1048984C (zh) * | 1991-12-20 | 2000-02-02 | 多坎化学有限公司 | 晶形1呋喃硝胺氢氯化物的制备 |
| US5721359A (en) * | 1993-03-12 | 1998-02-24 | Pharmacia & Upjohn Company | Crystalline ceftiofur free acid |
| DE4341310A1 (de) * | 1993-12-03 | 1995-06-08 | Hexal Pharma Gmbh | Tablette oder Kapsel mit einem Gehalt an stabilem Ranitidinhydrochlorid Form 1 |
| US5407687A (en) * | 1994-02-22 | 1995-04-18 | Glaxo Inc. | Ranitidine solid dosage form |
| EP0754182A1 (en) * | 1994-04-08 | 1997-01-22 | Brantford Chemicals Inc. | Form 1 ranitidine hydrochloride with increased density |
| CA2120874E (en) * | 1994-04-08 | 2002-01-08 | Keshava Murthy | Form of form 1 ranitidine |
| SK282424B6 (sk) | 1994-04-15 | 2002-01-07 | Pharmacia + Upjohn Company | "S" a "T" kryštalické formy 1-[5-metánsulfónamidoindolyl-2- karbonyl]-4-[3-(1-metyl-etylamino)-2-pyridinyl] piperazínu |
| IN181698B (https=) * | 1994-05-13 | 1998-09-05 | Ranbaxy Lab Ltd | |
| IN181699B (https=) * | 1994-05-13 | 1998-09-05 | Ranbaxy Lab Ltd | |
| NZ272054A (en) * | 1994-05-13 | 1996-05-28 | Ranbaxy Lab Ltd | Process for producing form 1 ranitidine hydrochloride |
| CN1148849A (zh) * | 1994-05-18 | 1997-04-30 | 赫彻斯特马里恩鲁斯公司 | 抗组胺哌啶衍生物，其多晶形物和假同晶物的无水和水合物形式的制备方法 |
| US20030045722A1 (en) * | 1994-05-18 | 2003-03-06 | Henton Daniel R. | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
| ES2122387T3 (es) | 1994-06-24 | 1998-12-16 | Ranbaxy Lab Ltd | Procedimiento para la preparacion de la forma 1 del clorhidrato de ranitidina. |
| WO1996016055A1 (en) * | 1994-11-18 | 1996-05-30 | Pharmacia & Upjohn Company | A new physically stable solid form of a fluoroquinolone |
| US5538737A (en) * | 1994-11-30 | 1996-07-23 | Applied Analytical Industries, Inc. | Oral compositions of H2 -antagonists |
| US5663381A (en) * | 1995-04-21 | 1997-09-02 | Hexal Pharmaceuticals, Inc. | Process for preparing form 1 ranitidine hydrochloride |
| US5686588A (en) * | 1995-08-16 | 1997-11-11 | Yoo; Seo Hong | Amine acid salt compounds and process for the production thereof |
| WO1997035853A1 (en) * | 1996-03-25 | 1997-10-02 | Hoechst Marion Roussel, Inc. | Process for the preparation of form 1 ranitidine hydrochloride |
| ATE196764T1 (de) * | 1997-08-08 | 2000-10-15 | Aventis Pharma Gmbh | Kristallform von 5-methylisoxazol-4-carbonsäure- (4-trifluormethyl)-anilid |
| US6287693B1 (en) | 1998-02-25 | 2001-09-11 | John Claude Savoir | Stable shaped particles of crystalline organic compounds |
| IT1317858B1 (it) * | 2000-02-29 | 2003-07-15 | Pharmexcel S R L | Allomorfo del cloridrato dell'isomero z di derivato dialchilamminofurano, procedimento per la sua produzione e composizione |
| GB2357762B (en) * | 2000-03-13 | 2002-01-30 | Lundbeck & Co As H | Crystalline base of citalopram |
| US20020183553A1 (en) * | 2000-10-19 | 2002-12-05 | Ben-Zion Dolitzky | Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof |
| US20060173064A1 (en) * | 2001-08-24 | 2006-08-03 | Lippa Arnold S | (-)-1-(3,4-Dichlorophenyl)-3-azabi cyclo[3.1.0]hexane, compositions thereof, and uses for treating alcohol-related disorders |
| US6569887B2 (en) * | 2001-08-24 | 2003-05-27 | Dov Pharmaceuticals Inc. | (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake |
| US7235655B2 (en) * | 2002-03-22 | 2007-06-26 | Pharmacia & Upjohn Company | Processes to prepare eplerenone |
| AR040661A1 (es) * | 2002-07-26 | 2005-04-13 | Theravance Inc | Diclorhidrato cristalino de n-{2-[-((r)-2-hidroxi-2-feniletilamino)fenil]etil}-(r)-2hidroxi-2-(3-formamido-4-hidroxifenil)etilamina, agonista del receptor adrenergico beta 2 |
| US20080081834A1 (en) | 2002-07-31 | 2008-04-03 | Lippa Arnold S | Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders |
| US7166641B2 (en) * | 2002-10-02 | 2007-01-23 | Yung Shin Pharmaceutical Industrial Co., Ltd. | Pharmaceutically acceptable salts containing local anesthetic and anti-inflammatory activities and methods for preparing the same |
| PL376604A1 (pl) * | 2002-11-08 | 2006-01-09 | Dov Pharmaceuticals, Inc. | Polimorfy chlorowodorku bicifadyny |
| TW200510277A (en) * | 2003-05-27 | 2005-03-16 | Theravance Inc | Crystalline form of β2-adrenergic receptor agonist |
| US7384557B2 (en) * | 2003-07-14 | 2008-06-10 | Applied Ambient Extraction Process Consultants, Llc | Method and apparatus for removing solute from a solid solute-bearing product |
| TWI328006B (en) * | 2003-12-26 | 2010-08-01 | Nissan Chemical Ind Ltd | Crystal form of quinoline compound and process for its production |
| US20070043100A1 (en) | 2005-08-16 | 2007-02-22 | Hagen Eric J | Novel polymorphs of azabicyclohexane |
| US20060100263A1 (en) * | 2004-11-05 | 2006-05-11 | Anthony Basile | Antipyretic compositions and methods |
| US20060100271A1 (en) * | 2004-11-08 | 2006-05-11 | Keith Whitehead | Stabilized aqueous ranitidine compositions |
| NZ592836A (en) | 2005-07-27 | 2013-01-25 | Dov Pharmaceutical Inc | Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders |
| DE102005035891A1 (de) * | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| US20080045725A1 (en) * | 2006-04-28 | 2008-02-21 | Murry Jerry A | Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane |
| AU2007309534B2 (en) * | 2006-10-20 | 2012-08-16 | Scinopharm Singapore Pte, Ltd. | Process for making crystalline anhydrous docetaxel |
| US8138377B2 (en) | 2006-11-07 | 2012-03-20 | Dov Pharmaceutical, Inc. | Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use |
| US9133159B2 (en) | 2007-06-06 | 2015-09-15 | Neurovance, Inc. | 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments |
| US20090069374A1 (en) * | 2007-06-06 | 2009-03-12 | Phil Skolnick | Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes, Methods For Their Preparation And Their Use As Medicaments |
| TW201011043A (en) * | 2008-06-20 | 2010-03-16 | Chugai Pharmaceutical Co Ltd | Crystal of spiroketal derivatives and process for preparation of spiroketal derivatives |
| PL2727912T3 (pl) | 2011-06-30 | 2017-12-29 | Toray Industries, Inc. | Kryształy pochodnej glicyny i ich zastosowanie farmaceutyczne |
| US20140206740A1 (en) | 2011-07-30 | 2014-07-24 | Neurovance, Inc. | Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters |
| CN106432149B (zh) * | 2015-05-26 | 2018-04-17 | 烟台市华文欣欣医药科技有限公司 | 一种制备治疗胃病的药物盐酸雷尼替丁化合物的方法 |
| CN105030694A (zh) * | 2015-08-04 | 2015-11-11 | 青岛蓝盛洋医药生物科技有限责任公司 | 一种治疗胃溃疡的药物盐酸雷尼替丁组合物干混悬剂 |
| CN104971053A (zh) * | 2015-08-05 | 2015-10-14 | 青岛蓝盛洋医药生物科技有限责任公司 | 一种治疗消化系统疾病的药物盐酸雷尼替丁组合物片剂 |
| CN105055331A (zh) * | 2015-08-31 | 2015-11-18 | 青岛蓝盛洋医药生物科技有限责任公司 | 一种治疗消化性溃疡的药物盐酸雷尼替丁组合物颗粒剂 |
| WO2021079183A1 (en) * | 2019-10-21 | 2021-04-29 | Sms Pharmaceuticals Limited | Isopropyl alcohol solvent free crystalline ranitidine hydrochloride form-2 which is free of nitrosamine (ndma) impurity |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1565966A (en) * | 1976-08-04 | 1980-04-23 | Allen & Hanburys Ltd | Aminoalkyl furan derivatives |
| US4233302A (en) * | 1977-12-23 | 1980-11-11 | Glaxo Group Limited | Amine derivatives and pharmaceutical compositions containing them |
-
1981
- 1981-09-28 IL IL63968A patent/IL63968A/xx unknown
- 1981-09-29 PT PT73744A patent/PT73744B/pt unknown
- 1981-10-01 JP JP56154887A patent/JPS5791983A/ja active Granted
- 1981-10-01 FR FR8118528A patent/FR2491067A1/fr active Granted
- 1981-10-01 DE DE19813139134 patent/DE3139134A1/de active Granted
- 1981-10-01 ZA ZA816809A patent/ZA816809B/xx unknown
- 1981-10-01 AT AT0422281A patent/AT389696B/de not_active IP Right Cessation
- 1981-10-01 IE IE2287/81A patent/IE51604B1/en not_active IP Right Cessation
- 1981-10-01 IT IT49407/81A patent/IT1143237B/it active
- 1981-10-01 GR GR66187A patent/GR72499B/el unknown
- 1981-10-01 DK DK436281A patent/DK167794B1/da not_active IP Right Cessation
- 1981-10-01 SE SE8105812A patent/SE453500B/sv not_active IP Right Cessation
- 1981-10-01 PH PH26300A patent/PH19489A/en unknown
- 1981-10-01 LU LU83661A patent/LU83661A1/fr unknown
- 1981-10-01 CH CH6322/81A patent/CH652122A5/fr not_active IP Right Cessation
- 1981-10-01 KR KR1019810003689A patent/KR870001431B1/ko not_active Expired
- 1981-10-01 ZW ZW244/81A patent/ZW24481A1/xx unknown
- 1981-10-01 BE BE0/206126A patent/BE890574A/fr not_active IP Right Cessation
- 1981-10-01 AU AU75955/81A patent/AU549119B2/en not_active Expired
- 1981-10-01 NZ NZ198522A patent/NZ198522A/en unknown
- 1981-10-01 CA CA000387135A patent/CA1202638A/en not_active Expired
- 1981-10-01 NL NL8104482A patent/NL8104482A/nl active Search and Examination
- 1981-10-01 ES ES505951A patent/ES8301954A1/es not_active Expired
-
1982
- 1982-08-09 US US06/406,710 patent/US4521431A/en not_active Expired - Lifetime
-
1985
- 1985-03-18 US US06/712,610 patent/US4672133A/en not_active Expired - Lifetime
- 1985-07-17 KE KE3549A patent/KE3549A/xx unknown
- 1985-12-05 HK HK979/85A patent/HK97985A/xx not_active IP Right Cessation
- 1985-12-20 PH PH33229A patent/PH21761A/en unknown
- 1985-12-30 MY MY747/85A patent/MY8500747A/xx unknown
-
1991
- 1991-12-23 SK SK4035-91A patent/SK277922B6/sk unknown
- 1991-12-23 CZ CS914035A patent/CZ280885B6/cs unknown
-
1992
- 1992-03-12 DK DK033792A patent/DK167923B1/da not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK277922B6 (en) | 2 ranitidine hydrochloride form, method of its preparation and pharmaceutical product with its contents | |
| SK285303B6 (sk) | Modifikácie 2-amino-4-(4-fluórbenzylamino)-1- etoxykarbonylaminobenzénu, spôsob ich prípravy, ich použitie a liečivá s ich obsahom | |
| US4313949A (en) | Method of producing an inhibitory effect on blood platelet aggregation | |
| JP3726291B2 (ja) | 安定な結晶構造を有するベンゾオキサジン化合物およびその製造法 | |
| WO2019063002A1 (zh) | 苯烯莫德的晶型及其用途与制备方法 | |
| SK288052B6 (sk) | Polymorph 1 of bilastine, process for preparing thereof, its antihistaminic and antiallergic use and pharmaceutical preparation containing it | |
| CN102321019A (zh) | 喹啉化合物的晶形及其生产方法 | |
| CN113966332A (zh) | Cdk9抑制剂的多晶型物及其制法和用途 | |
| CN102675395A (zh) | 醋酸乌利司他的多晶型及其制备方法 | |
| BRPI0616308A2 (pt) | novas formas de cristal de cloridrato de irinotecano | |
| CN112225732B (zh) | 一种盐酸哌罗匹隆水合物晶型及其制备方法 | |
| US4279914A (en) | Thrombocyte aggregation inhibiting composition and methods | |
| EP3558920B1 (en) | Improved synthesis of lysine acetylsalicylate · glycine particles | |
| CN116199729B (zh) | 乙酰氨基阿维菌素晶型b及其制备方法 | |
| TWI680983B (zh) | 一種鈉－葡萄糖共同轉運蛋白２抑制劑的ｌ－脯胺酸複合物、其一水合物及晶體 | |
| CN104093731A (zh) | [(2r,3s,4r,5r)-5-(6-(环戊基氨基)-9h-嘌呤-9-基)-3,4-二羟基四氢呋喃-2-基)]甲基硝酸酯的无水多晶型物及其制备方法 | |
| US5663381A (en) | Process for preparing form 1 ranitidine hydrochloride | |
| CN115974938A (zh) | 一种蔗糖七硫酸酯盐的合成方法 | |
| CN108026043A (zh) | 一种萘环化合物的晶型 | |
| CH626623A5 (https=) | ||
| KR101285050B1 (ko) | 결정형 1Ｈ-이미다조[4,5-ｂ]피리딘-5-아민,7-[5-[(시클로헥실메틸아미노)-메틸]-1Ｈ-인돌-2-일]-2-메틸, 설페이트 (1:1), 삼수화물 및 이의 약학적 용도 | |
| WO2020244148A1 (zh) | 多拉菌素晶型a、晶型b及其制备方法 | |
| CN111378002A (zh) | 一种环黄芪醇新晶型a及其制备方法 | |
| WO2019033851A1 (zh) | 一种噻吩并吡啶类衍生物硫酸氢盐的晶型 iii 及其制备方法和应用 | |
| CN120398892A (zh) | 巴瑞替尼的多晶型及其制备方法和应用 |